Fmoc-Val-Cit-PAB-OH
10mM in DMSO
- Product Code: 186834
CAS:
159858-22-7
| Molecular Weight: | 601.7 g./mol | Molecular Formula: | C₃₃H₃₉N₅O₆ |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD22417106 | |
| Melting Point: | 204 °C(dec.) | Boiling Point: | |
| Density: | Storage Condition: | -20°C, sealed, dry, light-proof |
Product Description:
Used in the synthesis of antibody-drug conjugates (ADCs), this compound serves as a linker that connects the antibody to a cytotoxic drug. The Fmoc-Val-Cit-PAB-OH contains a cleavable peptide sequence (Val-Cit) and a self-immolative spacer (PAB), which are critical for targeted drug release inside cancer cells. Upon internalization of the ADC into tumor cells, the Val-Cit dipeptide is selectively cleaved by lysosomal enzymes, particularly cathepsin B. This cleavage triggers the release of the active drug from the PAB spacer, enabling precise delivery and minimizing damage to healthy tissues. The Fmoc group allows for controlled stepwise solid-phase peptide synthesis, making it valuable in constructing complex ADC architectures. Its design enhances plasma stability while ensuring efficient intracellular activation, contributing to improved therapeutic efficacy and safety in cancer treatments.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 1ml | 10-20 days | ฿1,860.00 |
+
-
|
Fmoc-Val-Cit-PAB-OH
Used in the synthesis of antibody-drug conjugates (ADCs), this compound serves as a linker that connects the antibody to a cytotoxic drug. The Fmoc-Val-Cit-PAB-OH contains a cleavable peptide sequence (Val-Cit) and a self-immolative spacer (PAB), which are critical for targeted drug release inside cancer cells. Upon internalization of the ADC into tumor cells, the Val-Cit dipeptide is selectively cleaved by lysosomal enzymes, particularly cathepsin B. This cleavage triggers the release of the active drug from the PAB spacer, enabling precise delivery and minimizing damage to healthy tissues. The Fmoc group allows for controlled stepwise solid-phase peptide synthesis, making it valuable in constructing complex ADC architectures. Its design enhances plasma stability while ensuring efficient intracellular activation, contributing to improved therapeutic efficacy and safety in cancer treatments.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :